Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial

Trial Profile

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Elacestrant (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
  • Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EMERALD
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 30 Nov 2018 According to a Radius Health media release, the US. FDA recently granted Fast Track designation for the phase 3 study population (men and postmenopausal women with advanced ER+/HER2- breast cancer who have received at least 1 prior line of endocrine therapy, including prior cyclin-dependent kinase (CDK) 4/6 inhibitor therapy in combination with fulvestrant or an aromatase inhibitor).
    • 30 Nov 2018 According to a Radius Health media release, depending on the results, this single trial is intended to support applications for marketing approvals for elacestrant as a second- and third-line monotherapy in the U.S., European Union, and other markets.
    • 30 Nov 2018 Status changed from planning to recruiting, according to a Radius Health media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top